Last updated: February 24, 2025
Sponsor: AstraZeneca
Overall Status: Active - Recruiting
Phase
N/A
Condition
Copd (Chronic Obstructive Pulmonary Disease)
Treatment
N/AClinical Study ID
NCT06780046
D5980R00117
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients of both sexes, aged 18 years or older, with confirmed COPD according toGOLD 2024: previous or current exposure and spirometry (FEV1/FVC =2 or CAT >=10); or
GOLD E (>=2 moderate or 1 severe exacerbation - hospitalization); or
GOLD 3 and 4 (FEV1 <50%).
Exclusion
Exclusion Criteria:
Advanced fibrosing interstitial lung disease (extent >=50%); and/or
High-risk pulmonary hypertension (on triple therapy); and/or
Active cancer - on systemic therapy
Study Design
Total Participants: 693
Study Start date:
January 31, 2025
Estimated Completion Date:
August 31, 2027
Study Description
Connect with a study center
Centro de Pesquisa Clinica do Instituto Israelita de Ensino (HIAE)
Sao Paulo,
BrazilActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.